Bausch Health Co. Inc. (BHC) reported Q2 EPS of ($0.40), $1.29 worse than the analyst estimate of $0.89. Revenue for the quarter came in at $1.97 billion versus the consensus...
This article was written exclusively for Investing.com Purely from a fundamental perspective, Jumia Technologies (NYSE:JMIA) stock looks like a zero, or something close. Indeed,...
The coming trading week promises to be both busy and potentially volatile as a torrent of Wall Street's most prominant mega caps report quarterly metrics. The list includes...
Don’t get me wrong—I love my kids. It’s just that I’ve loved “hidden yields” longer. What are these long-term affectionate affairs of mine?...
Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company develops, manufactures, and markets, primarily in the therapeutic areas of eye health, gastroenterology (GI), and dermatology, a range of branded, generic and branded generic pharmaceuticals, over the counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. The Company operates through five segments: Bausch + Lomb, Salix, International, Solta Medical, and Diversified Products. The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical, and Ophthalmic Pharmaceuticals products. The Salix segment consists of sales in the United States of gastrointestinal (GI) products. The Solta Medical segment consists of global sales of Solta aesthetic medical devices.
|Average||13.67 (+98.40% Upside)|
|No. of Analysts||9|